Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Merck and : Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CEST

Release date- 02102017 - EAGAN, MN - Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera's novel phase 2 cancer immunotherapy.

These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI- EORTC will feature initial translational research from Biothera's ongoing phase 2 clinical study combining Imprime PGG and Merck's anti-PD-1 antibody, Keytruda, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.

About Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.

Contact:

David Walsh

Tel: 651-256-4606

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
06/23MERCK : Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT..
BU
06/22MERCK AND : FDA restricts Keytruda, Tecentriq monotherapy
AQ
06/21AGILENT TECHNOLOGIES : Companion Diagnostic Gains Expanded FDA Approval in Cervi..
AQ
06/21MERCK AND : - Late-Breaking Data to be presented from the Comparative Trials wit..
AQ
06/21MERCK AND : CEO Kenneth Frazier, speaking in Philly, urges people to call out 'u..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/18MERCK AND : Late-Breaking Data to be Presented from the Comparative Trials with ..
PU
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/15MERCK AND : Modern Alchemists Are Making Chemistry Greener
AQ
06/15MERCK AND : `s Keytruda snags I-O`s first cervical cancer nod to back up HPV fig..
AQ
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/21Key events next week - healthcare 
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
06/19ALZHEIMER'S DISEASE : A History Of Drug Failures 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,17%
P/E ratio 2018 23,66
P/E ratio 2019 15,99
EV / Sales 2018 4,31x
EV / Sales 2019 4,10x
Capitalization 165 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 69,1 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY9.24%165 373
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-10.81%191 785
AMGEN6.47%122 515